SOP1812 |
| カタログ番号GC65887 |
SOP1812 は、抗腫瘍活性を持つナフタレンジイミド (ND) 誘導体です。 SOP1812 は四重鎖配置 (G4) に結合し、いくつかの癌遺伝子経路をダウンレギュレートします。 SOP1812 は、hTERT G4 および HuTel21 G4 に対して高い親和性を示し、KD 値はそれぞれ 4.9 および 28.4 nM です。 SOP1812 は、がんの研究に使用できます。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2546091-70-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SOP1812 is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer[1].
SOP1812 (0-50 nM; 96 h) inhibits the proliferation of many cancer cells[1].
SOP1812 (0-800 nM; 6-24 h) shows great affinity to hTERT G4 and HuTel21 G4[1].
SOP1812 (40 nM; 6-24 h) affects Wnt/β-catenin, axon guidance, Hippo, MAPK and Rap1 pathways[1].
Cell Proliferation Assay[1]
| Cell Line: | MIA PaCa-2, PANC-1, Capan-1 and BxPC-3 cell lines |
| Concentration: | 0-50 nM |
| Incubation Time: | 96 hours |
| Result: | Showed anti-proliferation ability to MIA PaCa-2, PANC-1, Capan-1 and BxPC-3 cells with GI50 values of 1.3, 1.4, 5.9 and 2.6 nM, respectively. |
Cell Viability Assay[1]
| Cell Line: | PANC-1 cells |
| Concentration: | 0, 100, 400 and 800 nM |
| Incubation Time: | 6 and 24 hours |
| Result: | Binded to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. |
Cell Viability Assay[1]
| Cell Line: | MIA PaCa-2 Cells |
| Concentration: | 40 nM |
| Incubation Time: | 6 and 24 hours |
| Result: | Affected WNT5B, DVL1, AXIN and APC2 expression which includes in Wnt/β-catenin pathway and also showed effects on axon guidance, Hippo, MAPK, and Rap1 pathways. |
SOP1812 (1 mg/kg; i.v. once or twice per week for 28 days) shows anti-tumor activity in MIA PaCa-2 xenografts mice and KPC mice[1].
| Animal Model: | Female athymic nude mice with MIA PaCa-2 xenografts[1] |
| Dosage: | 1 mg/kg |
| Administration: | Intravenous injection; 1 mg/kg once or twice per week; for 28 days |
| Result: | Showed complete tumor regression and no significant tumor regrowth after day 28 on several animals. |
| Animal Model: | KPC mice with PDAC symptoms[1] |
| Dosage: | 1 mg/kg |
| Administration: | Intravenous injection; 1 mg/kg once per week; for 3 weeks |
| Result: | Significantly extended survival of KPC mice and showed a better effect than gemcitabine. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *